Genmab jumps after positive trial of AbbVie-partnered lymphoma drug
Genmab and AbbVie reported that their drug epcoritamab, when combined with standard treatment, reduced the risk of cancer progression or death by 51% in a Phase 3 trial for diffuse large B-cell lymphoma. The companies plan to discuss the findings with regulators. Genmab's shares rose 9%, while AbbVie's futures remained flat.
How this was made
The 30-second read
Why it matters
The trial's statistically significant 51% risk reduction is a material clinical milestone, likely to trigger label expansion discussions and boost investor interest.
Market read
First‑report pivotal trial data creates immediate buying interest in both partners, with broader implications for the lymphoma treatment market.
What to watch
Potential competition from other bispecific antibodies and the need for pricing negotiations with payers.
Background
Genmab and AbbVie co‑develop epcoritamab, a bispecific antibody targeting CD3 and CD20, for first‑line treatment of diffuse large B‑cell lymphoma.
Ticker impact
Genmab announced Phase 3 trial data showing epcoritamab added to R-CHOP cuts risk of progression or death by 51%, sending its shares up 9% in Copenhagen.
upward pressure as investors price in potential label expansion and future sales.
First disclosure of pivotal Phase 3 results with a large relative risk reduction and immediate 9% share jump.
AbbVie, partner in the epcoritamab trial, reported the same 51% risk reduction, supporting its pipeline and potential future revenue.
slight upward pressure as the market credits the partner's data to AbbVie's oncology franchise.
AbbVie futures were flat at the time, but the trial outcome adds a positive catalyst to its pipeline.
Market effects
Strengthens confidence in lymphoma immunotherapy approaches, may boost related biotech stocks.
Positive for European biotech markets, especially Copenhagen-listed firms.
Adds to global oncology pipeline momentum, could influence investor sentiment toward biotech ETFs.
Counterpoint
If regulatory approval is delayed or data later shows safety concerns, the initial rally could reverse.
Key entities
- companyGenmab A/S
Danish biotech developing epcoritamab, listed on Nasdaq as GMAB.
- companyAbbVie Inc.
US pharmaceutical partner, listed on NYSE as ABBV.
